Literature DB >> 18177582

Weight reduction for treatment of obesity-associated hypertension: nuances and challenges.

Allyn L Mark1.   

Abstract

Weight reduction is generally recommended as the first line of treatment for the increasing problem of obesity-associated hypertension. At first glance, this recommendation seems compelling, but evidence suggests that weight loss for obesity-associated hypertension is neither simple nor consistently effective as antihypertensive therapy. First, dietary and behavioral therapy is accompanied by an extremely high rate of weight regain after loss. Mounting evidence shows that this recidivism reflects neurobiologic and not simply psychologic adaptations to dietary restriction. Second, chronic blood pressure-lowering effects of weight loss produced by diet, weight-reducing drugs, or bariatric surgery may not be as pronounced as commonly thought. Third, there is evidence that dietary restriction, independent of weight loss, reduces sympathetic nervous system activity and might thereby contribute to reducing blood pressure. This phenomenon deserves more consideration in designing and interpreting studies of blood pressure changes during diet-induced weight loss. This article reviews these issues and highlights the nuances and challenges in the effectiveness of weight loss for treatment of obesity-induced hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177582     DOI: 10.1007/s11906-007-0068-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  43 in total

Review 1.  The drive to regain is mainly in the brain.

Authors:  Barry E Levin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-12       Impact factor: 3.619

Review 2.  A teleological view of obesity, diabetes and hypertension.

Authors:  Lewis Landsberg
Journal:  Clin Exp Pharmacol Physiol       Date:  2006-09       Impact factor: 2.557

3.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

4.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Authors:  Jean-Pierre Després; Alain Golay; Lars Sjöström
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

6.  Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group.

Authors: 
Journal:  Arch Intern Med       Date:  1997-03-24

7.  Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.

Authors:  Andreas L Birkenfeld; Christoph Schroeder; Tobias Pischon; Jens Tank; Friedrich C Luft; Arya M Sharma; Jens Jordan
Journal:  Clin Auton Res       Date:  2005-06       Impact factor: 4.435

8.  Role of selective leptin resistance in diet-induced obesity hypertension.

Authors:  Kamal Rahmouni; Donald A Morgan; Gina M Morgan; Allyn L Mark; William G Haynes
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

9.  Effect of body weight loss on blood pressure after 6 years of follow-up in stage 1 hypertension.

Authors:  Mikolaj Winnicki; Elisa Bonso; Francesca Dorigatti; Daniele Longo; Vania Zaetta; Mauro Mattarei; Daniele D'Este; Giorgio Laurini; Achille C Pessina; Paolo Palatini
Journal:  Am J Hypertens       Date:  2006-11       Impact factor: 2.689

Review 10.  Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications.

Authors:  Allyn L Mark; Marcelo L G Correia; Kamal Rahmouni; William G Haynes
Journal:  J Hypertens       Date:  2002-07       Impact factor: 4.844

View more
  6 in total

1.  Adiposity-independent sympathetic activity in black men.

Authors:  Aamer Abbas; Lidia S Szczepaniak; Meryem Tuncel; Jonathan M McGavock; Beverley Huet; Paul J Fadel; Zhongyun Wang; Debbie Arbique; Ronald Victor; Wanpen Vongpatanasin
Journal:  J Appl Physiol (1985)       Date:  2010-03-18

2.  Sympathetic inhibition after bariatric surgery.

Authors:  Allyn L Mark; Andrew W Norris; Kamal Rahmouni
Journal:  Hypertension       Date:  2014-08       Impact factor: 10.190

3.  Obesity-related hypertension.

Authors:  Richard N Re
Journal:  Ochsner J       Date:  2009

Review 4.  The brain melanocortin system, sympathetic control, and obesity hypertension.

Authors:  Alexandre A da Silva; Jussara M do Carmo; Zhen Wang; John E Hall
Journal:  Physiology (Bethesda)       Date:  2014-05

5.  DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre.

Authors:  Y Al-Solaiman; A Jesri; W K Mountford; D T Lackland; Y Zhao; B M Egan
Journal:  J Hum Hypertens       Date:  2009-07-23       Impact factor: 3.012

Review 6.  Is surgery the next answer to treat obesity-related hypertension?

Authors:  Eldo E Frezza; Cai Wei; Mitchell S Wachtel
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-05       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.